Publicacións en colaboración con investigadores/as de University of Nantes (7)

2023

  1. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

    Leukemia, Vol. 37, Núm. 7, pp. 1521-1529

2019

  1. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Leukemia, Vol. 33, Núm. 1, pp. 159-170

  2. Insights on Multiple Myeloma Treatment Strategies

    HemaSphere, Vol. 3, Núm. 1

2017

  1. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

    British Journal of Haematology, Vol. 177, Núm. 3, pp. 404-413

2016

  1. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma

    Journal of Clinical Oncology, Vol. 34, Núm. 32, pp. 3921-3930

2015

  1. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152

2003

  1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group

    British Journal of Haematology, Vol. 121, Núm. 5, pp. 749-757